Literature DB >> 1428716

Subconjunctival sustained release 5-fluorouracil.

D L Blandford1, T J Smith, J D Brown, P A Pearson, P Ashton.   

Abstract

The authors have developed a sustained release device for 5-fluorouracil (5-FU) made up of a 12 mg pellet of drug coated in a mixture of permeable and impermeable polymers. When implanted subconjunctivally in rabbits, these devices released 5-FU at approximately 1 mg/d for over 10 days. Devices were implanted into four cynomolgus monkey eyes after posterior lip sclerotomy. One eye (treatment) received a device that contained 12 mg 5-FU and the other eye (control) received a placebo device that contained no drug. In control eyes, intraocular pressures returned to normal within 1 wk. In treatment eyes, pressures remained significantly lower throughout the experimental period (3 mo). There was no indication of impaired wound healing, corneal toxicity, inflammation, or damage to the ciliary body in rabbits or monkeys.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1428716

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  2 in total

1.  Effects of Gelatin Hydrogel Containing Anti-Transforming Growth Factor-β Antibody in a Canine Filtration Surgery Model.

Authors:  Michiko Maeda; Shota Kojima; Tetsuya Sugiyama; Denan Jin; Shinji Takai; Hidehiro Oku; Ryohsuke Kohmoto; Mari Ueki; Tsunehiko Ikeda
Journal:  Int J Mol Sci       Date:  2017-05-05       Impact factor: 5.923

Review 2.  Intravitreal devices for the treatment of vitreous inflammation.

Authors:  John B Christoforidis; Susie Chang; Angela Jiang; Jillian Wang; Colleen M Cebulla
Journal:  Mediators Inflamm       Date:  2012-09-05       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.